Nexus BioPharma, Inc., (OTC-BB NEXS), a company specializing in the development of a weight loss drug therapy, announced today the appointment of Jeffrey Pessin, Ph.D. as Chairman of the Company's Scientific Advisory Board. Dr. Pessin is the Judy R. & Alfred A. Rosenberg Professorial Chair in Diabetes Research and Director of the Diabetes Research Center, Department of Medicine at the Albert Einstein College of Medicine. He also serves as Professor in the Departments of Medicine (Endocrinology) and Molecular Pharmacology.

"Dr. Pessin is an internationally recognized research scientist, and he brings specific expertise as the discoverer of our weight loss technology," said Mr. Warren C. Lau, Chief Executive Officer and President of Nexus BioPharma, Inc. Mr. Lau continued "His breakthrough discovery could result in a safe and effective weight loss treatment for overcoming the obesity and type 2 diabetes epidemics."

About Nexus BioPharma, Inc. www.nexusbiopharma.com

Nexus BioPharma, Inc. is developing a weight loss drug that activates the AMPK metabolic pathway, the same pathway activated by intense physical exercise.